Zevra Therapeutics (ZVRA) Earnings Analysis

Zevra Therapeutics (ZVRA) has no confirmed upcoming earnings date. Last quarter (2026-03-09) it beat with EPS 1.16 USD vs 0.0504 USD est (+2201.6%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E 5.57.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ZVRA next report earnings?

No confirmed upcoming earnings date is currently scheduled for ZVRA. This page updates as the calendar is published.

ZVRA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-091.16 USD0.0504 USD+2201.6%Beat
2025-08-121.21 USD2.19 USD-44.7%Miss
2025-03-11-0.67 USD-0.39 USD-71.8%Miss

Beat rate: 1/3 (33%) over reported quarters with consensus data.

ZVRA valuation and analyst view

Trailing P/E5.57
Trailing EPS2.127 USD
Price / book3.45
Dividend yield0.00%
Market cap0.72B
Analyst consensusBuy (10 buy / 0 hold / 0 sell)
Avg price target29.5 USD

Related research pages

Frequently asked questions

When is Zevra Therapeutics (ZVRA)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for ZVRA. This page updates as the calendar is published.

Did ZVRA beat earnings last quarter?

In its 2026-03-09 report, ZVRA posted EPS of 1.16 USD versus a 0.0504 USD estimate — a beat of 2201.6%.

What is ZVRA's earnings track record?

Over the last 3 reported quarters with consensus data, ZVRA beat estimates 1 times (33%).

What is ZVRA's current P/E ratio and EPS?

ZVRA trades at a trailing P/E of 5.57 on trailing EPS of 2.1268036795220624 USD.

What do analysts rate ZVRA?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 29.5 USD.